| Species |
Human |
| Protein Construction |
VEGF165 (Ala27-Arg191)_x000D_
Accession # P15692-4 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 0.05EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized VEGF165, Human at 1μg/ml(100μl/well) on the plate can bind Biotinylated Human VEGFR1, His Tag. Test result was comparable to standard batch.
Measured by a reporter gene assay using HEK293TKDRNFAT Cell line. The ED50 for this effect is< 10 ng/mL. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 20-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis. |
| Synonyms |
VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
